ENT’s and Allergy Clinicians (MDs and APPs)
Allergy/Immunology, CRSwNP
Associate Chief
Clinical Research and Practice Innovation
Division of Allergy/Immunology
Northwestern University Feinberg School of Medicine
Chicago, IL
Anju T. Peters, MD, MS is a Professor in the Department of Medicine and Department of Otolaryngology Head & Neck Surgery. She graduated from University of Michigan Medical School and completed her residency and fellowship in the Division of Allergy-Immunology at Northwestern University Feinberg School of Medicine. She currently serves as the Director of Clinical Research in the Division of Allergy-Immunology at Northwestern University Feinberg School of Medicine. She is also the Medical Director of the Northwestern Medicine Clinical Research Unit.
Clinical Assistant Professor
Department of Otolaryngology
University of Central Florida College of Medicine
Orlando, FL
Dr. Cecelia Damask, DO, FAOCOHNS, FAAOA, is a comprehensive otolaryngologist, with a specialty focus on Allergy and Sinus Diseases, and Assistant Professor in the Department of Otolaryngology at the University of Central Florida College of Medicine. She has extensive training in the treatment of allergies and is an expert in the use of biologics for the treatment of allergic disorders. Dr. Damask is passionate about providing her patients with the highest quality care and is committed to using the latest evidence-based treatments to help her patients achieve optimal health.
| 1. | UTILIZE clinical and inflammatory features that guide biologic selection and signal recurrence risk in CRSwNP | 2. | DETERMINE how and when to incorporate biologics into CRSwNP management and sequencing treatment before, after, or in place of FESS |
| 3. | IMPLEMENT treatment strategies that incorporate biologics as add-on maintenance therapy for type 2 inflammation in CRSwNP, based on emerging guidance | 4. | STRENGTHEN cross-specialty collaboration between ENTs and allergists to ensure timely, coordinated care and appropriate integration of biologic therapies in CRSwNP |
| 1. | UTILIZE clinical and inflammatory features that guide biologic selection and signal recurrence risk in CRSwNP |
| 2. | DETERMINE how and when to incorporate biologics into CRSwNP management and sequencing treatment before, after, or in place of FESS |
| 3. | IMPLEMENT treatment strategies that incorporate biologics as add-on maintenance therapy for type 2 inflammation in CRSwNP, based on emerging guidance |
| 4. | STRENGTHEN cross-specialty collaboration between ENTs and allergists to ensure timely, coordinated care and appropriate integration of biologic therapies in CRSwNP |

In collaboration with
ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT
This activity is supported by an educational grant from Regeneron
TITLE: Emerging Biologic Strategies for Chronic Rhinosinusitis with Nasal Polyps
Release | Expiration: February XX, 2026 – February XX, 2027
STATEMENT OF NEED
Despite recent advances, several challenges continue to limit optimal use of biologics in CRSwNP. ENTs and allergists may underrecognize key clinical, inflammatory, and comorbid features that help identify candidates for biologic therapy and predict recurrence risk. Uncertainty persists around when to initiate biologics in relation to endoscopic sinus surgery, with limited guidance on whether they should be used before, after, or in place of surgery. The absence of U.S. specific position statements further contributes to variability in identifying which patients are appropriate candidates for biologics, determining the optimal timing of biologic initiation related to FESS, and selecting the best agent based on clinical and inflammatory profiles. In addition, poor communication between ENT and allergy teams often results in fragmented care, delayed decisions, and inconsistent treatment approaches
EDUCATIONAL OBJECTIVES
UTILIZE clinical and inflammatory features that guide biologic selection and signal recurrence risk in CRSwNP
DETERMINE how and when to incorporate biologics into CRSwNP management and sequencing treatment before, after, or in place of FESS
IMPLEMENT treatment strategies that incorporate biologics as add-on maintenance therapy for type 2 inflammation in CRSwNP, based on emerging guidance
STRENGTHEN cross-specialty collaboration between ENTs and allergists to ensure timely, coordinated care and appropriate integration of biologic therapies in CRSwNP
TARGET AUDIENCE
ENT’s and Allergy Clinicians (MDs and APPs)
FACULTY
![]() | Cecelia Damask, DO, FAOCOHNS, FAAOA AdventHealth[CT1] - Orlando ENT & Allergy Assistant Professor – Department of Otolaryngology University of Central Florida Orlando, FL |
| Disclosures | No relevant relationships |
![]() | Anju T. Peters, MD, MSCI Director, Center for Clinical Research |
| Disclosures | No relevant relationships |
TECHNICAL WRITER
Erika K. Lunz, PharmD
Disclosures
No relevant financial disclosures
PEER REVIEWER
Leonard Bacharier, MD FAAAAI
Disclosures
No relevant financial disclosures
ACCREDITED PROVIDER DISCLOSURE
None of the planners, reviewers, and AAAAI and RealCME staff for this educational activity have relevant financial relationship(s) with ineligible companies to disclose.
DISCLOSURE OF FINANCIAL RELATIONSHIPS POLICY
AAAAI adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME/CE activity, including faculty, planners, reviewers, or others are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
ACCREDITED PROVIDER & ACCREDITATION STATEMENTS
This activity is accredited through AAAAI.
CME: The American Academy of Allergy Asthma and Immunology (AAAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CE: The American Academy of Allergy Asthma and Immunology (AAAAI) is a Provider approved by the California Board of Registered Nursing, Provider #10704.
CREDIT DESIGNATION STATEMENT
The AAAAI designates this activity for up to 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
DISCLOSURE OF UNLABELED USE
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a clinician relative to diagnostic and treatment options for a specific patient's medical condition.
Disclaimer
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AAAAI and RealCME. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
If you have any questions relating to the accreditation of this activity, please contact cme@aaaai.org
METHOD OF PARTICIPATION/INSTRUCTIONS
Please proceed with the activity until you have successfully answered all test questions, completed the evaluation, and have received a digital copy of your credit certificate.
PRIVACY STATEMENT
The American Academy of Allergy, Asthma & Immunology (AAAAI) takes your privacy seriously. AAAAI will only use your personal information to administer your registration, attendance, and credit claiming/attendance record for this activity, to provide services that you have requested from AAAAI and otherwise as you may expressly consent. A complete copy of AAAAI’s Legal and Privacy Notices, the terms of which are incorporated herein, can be found here.
By providing consent, you are allowing AAAAI to process your personal data. AAAAI will collect and store information you provide in the Registration Forms for the purposes of enabling us to register your attendance at the activity; to assist with administrative, planning and marketing purposes; and to allow the compilation and analysis of statistics relevant to AAAAI.
The information you provide in the Registration Forms, and information provided at any other time during this activity, including without limitation any feedback obtained during the activity, will be used by AAAAI to offer, provide and continue to improve its educational activities and other services. The AAAAI may also use your email address to communicate important information regarding this activity and for marketing purposes for future activities. AAAAI will not otherwise, without your consent, use or disclose your personal information for any purpose unless it would reasonably be expected that such a purpose is related to the offer, provision and improvement of the activity or where such purpose is permitted or required by law.
I understand that it is my right to withhold consent to the above Privacy and Data Protection Notice, or to withdraw my previous consent at any time. I further understand that without my consent, it is not possible to process my registration/housing request for this activity. Please contact the AAAAI Education Team at (414) 272-6071 if you have any further questions about how this will affect your registration request for this activity.
COURSE VIEWING REQUIREMENTS
| Supported Browsers: Microsoft Edge Google Chrome 60 or higher Mozilla Firefox 60 or higher Apple Safari 11.0 or higher For video, install the latest version of Quicktime. | Supported Phones & Tablets: iOS 9.3 and higher Android 7.0 (Nougat or higher) Microsoft Windows 8 Chrome OS |
| Additional Recommendations and Requirements | |
| Display Resolution & Color Depth | Resolution - 960 X 768 minimum - 1024 X 768 recommended min. Color Depth - 8 bits (256 colors) minimum - 16 bits (High colors) minimum |
| Audio | - Microphone - Speakers or headphones - Audio recording support |
| Word Processing | Software that can open, modify, and save documents in Rich Text Format (RTF). Microsoft Word and PowerPoint are recommended. |